AU2018353122B2 - Amine-substituted heterocyclic compounds as EHMT2 inhibitors, salts thereof, and methods of synthesis thereof - Google Patents

Amine-substituted heterocyclic compounds as EHMT2 inhibitors, salts thereof, and methods of synthesis thereof Download PDF

Info

Publication number
AU2018353122B2
AU2018353122B2 AU2018353122A AU2018353122A AU2018353122B2 AU 2018353122 B2 AU2018353122 B2 AU 2018353122B2 AU 2018353122 A AU2018353122 A AU 2018353122A AU 2018353122 A AU2018353122 A AU 2018353122A AU 2018353122 B2 AU2018353122 B2 AU 2018353122B2
Authority
AU
Australia
Prior art keywords
compound
crystalline form
radiation
xrpd pattern
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018353122A
Other languages
English (en)
Other versions
AU2018353122A1 (en
Inventor
John Emmerson Campbell
Kenneth William Duncan
James Edward John Mills
Michael John Munchhof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epizyme Inc
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of AU2018353122A1 publication Critical patent/AU2018353122A1/en
Application granted granted Critical
Publication of AU2018353122B2 publication Critical patent/AU2018353122B2/en
Priority to AU2024201165A priority Critical patent/AU2024201165A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018353122A 2017-10-18 2018-10-18 Amine-substituted heterocyclic compounds as EHMT2 inhibitors, salts thereof, and methods of synthesis thereof Active AU2018353122B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201165A AU2024201165A1 (en) 2017-10-18 2024-02-22 Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762573917P 2017-10-18 2017-10-18
US62/573,917 2017-10-18
PCT/US2018/056428 WO2019079540A1 (en) 2017-10-18 2018-10-18 AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF EHMT2, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201165A Division AU2024201165A1 (en) 2017-10-18 2024-02-22 Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof

Publications (2)

Publication Number Publication Date
AU2018353122A1 AU2018353122A1 (en) 2020-06-04
AU2018353122B2 true AU2018353122B2 (en) 2023-11-23

Family

ID=66173899

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018353122A Active AU2018353122B2 (en) 2017-10-18 2018-10-18 Amine-substituted heterocyclic compounds as EHMT2 inhibitors, salts thereof, and methods of synthesis thereof
AU2024201165A Pending AU2024201165A1 (en) 2017-10-18 2024-02-22 Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201165A Pending AU2024201165A1 (en) 2017-10-18 2024-02-22 Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof

Country Status (16)

Country Link
US (2) US20200247790A1 (enExample)
EP (1) EP3697762A4 (enExample)
JP (2) JP2021500334A (enExample)
KR (1) KR20200101330A (enExample)
CN (1) CN111417628A (enExample)
AU (2) AU2018353122B2 (enExample)
BR (1) BR112020007632A2 (enExample)
CA (1) CA3079273A1 (enExample)
CL (1) CL2020001009A1 (enExample)
CO (1) CO2020005944A2 (enExample)
EA (1) EA202090959A1 (enExample)
IL (2) IL301746B2 (enExample)
MA (1) MA50418A (enExample)
MX (2) MX2020007152A (enExample)
SG (1) SG11202003225YA (enExample)
WO (1) WO2019079540A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110446495B (zh) 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
US11672800B2 (en) 2017-04-21 2023-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN114249785B (zh) * 2020-09-23 2024-04-05 常州方圆制药有限公司 一种2-腺苷n-吡唑的衍生物瑞加德松的制备方法
JP2023546729A (ja) * 2020-10-27 2023-11-07 トレベナ・インコーポレイテッド デルタオピオイドモジュレーターの結晶形及び非晶形
WO2025240956A1 (en) * 2024-05-17 2025-11-20 Yale University G9a/ehmt2 inhibitor use for prader-willi syndrome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017181177A1 (en) * 2016-04-15 2017-10-19 Epizyme, Inc. Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
WO2018118842A1 (en) * 2016-12-19 2018-06-28 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505858A (ja) * 2003-09-18 2007-03-15 ノバルティス アクチエンゲゼルシャフト 増殖性障害の処置に有用な２，４−ジ（フェニルアミノ）ピリミジン
NZ592990A (en) * 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US9284272B2 (en) * 2014-03-28 2016-03-15 Abbvie Inc. Inhibitors of histone methyltransferase G9a
ES2769648T3 (es) * 2014-06-16 2020-06-26 Fundacion Para La Investig Medica Aplicada Nuevos compuestos como inhibidores duales de histona metiltransferasas y ADN metiltransferasasASAS
US20170209444A1 (en) * 2014-06-23 2017-07-27 Genentech Inc. Methods of treating cancer and preventing cancer drug resistance
AU2018243749A1 (en) * 2017-03-31 2019-11-21 Epizyme, Inc. Methods of using EHMT2 inhibitors
EP3697420A4 (en) * 2017-10-18 2021-11-24 Epizyme, Inc. METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017181177A1 (en) * 2016-04-15 2017-10-19 Epizyme, Inc. Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
WO2018118842A1 (en) * 2016-12-19 2018-06-28 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof

Also Published As

Publication number Publication date
US20220324851A1 (en) 2022-10-13
IL301746B1 (en) 2024-09-01
SG11202003225YA (en) 2020-05-28
CA3079273A1 (en) 2019-04-25
CL2020001009A1 (es) 2020-12-18
EA202090959A1 (ru) 2020-07-13
MX2024012124A (es) 2025-02-10
IL273974B2 (en) 2023-08-01
KR20200101330A (ko) 2020-08-27
EP3697762A4 (en) 2021-04-07
IL301746B2 (en) 2025-01-01
MA50418A (fr) 2021-04-07
CO2020005944A2 (es) 2020-07-31
JP2021500334A (ja) 2021-01-07
IL273974B1 (en) 2023-04-01
MX2020007152A (es) 2020-12-10
WO2019079540A1 (en) 2019-04-25
US20200247790A1 (en) 2020-08-06
AU2024201165A1 (en) 2024-03-14
IL301746A (en) 2023-05-01
IL273974A (en) 2020-05-31
BR112020007632A2 (pt) 2020-09-29
JP2023036991A (ja) 2023-03-14
EP3697762A1 (en) 2020-08-26
AU2018353122A1 (en) 2020-06-04
CN111417628A (zh) 2020-07-14

Similar Documents

Publication Publication Date Title
AU2018353122B2 (en) Amine-substituted heterocyclic compounds as EHMT2 inhibitors, salts thereof, and methods of synthesis thereof
EP3555070B1 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
KR102563325B1 (ko) Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
KR102469161B1 (ko) Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
JP7425724B2 (ja) Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体
BG107460A (bg) Производни на бензимидазола, тяхното получаване иприложението им в терапията
CN108314677A (zh) 一种新型的ezh2抑制剂及其用途
WO2019158025A1 (zh) 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
JP2022504620A (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
US20220274961A1 (en) Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors
KR20240021239A (ko) Cdk 키나아제 억제제로 사용되는 화합물 및 이의 용도
CN103833756B (zh) 一类哒嗪酮类化合物及其制备方法和用途
WO2025007801A1 (zh) 一种嘌呤类衍生物及其用途
WO2018001332A1 (zh) 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途
JP2022529643A (ja) プロテインキナーゼ阻害剤としてのベンゾ－およびピリド－ピラゾール
WO2011082271A2 (en) Substituted triazolo-pyrimidine compounds
TW202434590A (zh) 稠合雙環化合物
WO2025223561A1 (zh) 一种喹唑啉酮并五元杂环化合物及其药用组合物和用途
EA048322B1 (ru) Гетероциклические соединения в качестве ингибиторов bet
WO2024148184A1 (en) Compounds and processes for the preparation of jak inhibitors
NZ795530A (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)